Doses to organs at risk calculated using plato and oncentra softwares in intracavitary brachytherapy
This is a retrospective study, the organ doses of the bladder and the rectum were compared between routine PLATO V14.2.3 (Nucletron B.V., Veenendaal, The Netherlands) and newer version software Oncentra MasterPlan (OMP) V4.3 (Nucletron B.V., Veenendaal, The Netherlands) treatment planning system...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Penerbit Universiti Kebangsaan Malaysia
2021
|
| Online Access: | http://journalarticle.ukm.my/16637/ http://journalarticle.ukm.my/16637/1/40401-147282-1-PB.pdf |
| Summary: | This is a retrospective study, the organ doses of the bladder and the rectum were compared between routine PLATO
V14.2.3 (Nucletron B.V., Veenendaal, The Netherlands) and newer version software Oncentra MasterPlan (OMP) V4.3
(Nucletron B.V., Veenendaal, The Netherlands) treatment planning systems (TPS). The treatment data of 32 intracavitary
brachytherapy patients at Hospital Universiti Sains Malaysia from January 2010 to June 2015 were used. These data
sets were used for catheter reconstruction for both PLATO and OMP TPS followed by independent verification using
Excel. There was no significant difference in mean doses to organs at risk (OARs) that calculated by both TPS (p>0.05).
The mean percentage of doses calculated by PLATO TPS for bladder and rectum were 66.58 ± 27.42% and 46.27 ±
14.47%, respectively. While, the mean percentage of doses for bladder and rectum calculated by OMP TPS were 65.68
± 24.24% and 46.46 ± 16.66%, respectively. The mean percentage difference in doses comparison between independent
verification calculation and PLATO TPS was 1.96 ± 6.00% and then became 6.37 ± 5.17% when it was compared with
OMP TPS. Overall, the dose calculation differences for both versions of TPS were within the range recommended by
Nuclear Regulatory Commission (NRC). The dose calculations of the two treatment planning systems showed good
agreement and both could be used in planning intracavitary brachytherapy for cervical cancer. Whereas, Excel based
independent verification is suitable to be implemented as routine dose verification programme prior to treatment
delivery. |
|---|